Considering the potential benefits, combining the conversion of global hypomethylation to hypermethylation in melanoma with other targeted therapies like molecularly targeted tyrosine kinase inhibitors (TKIs), BRAF, MEK, etc. could enhance treatment efficacy for patients. This evidence concerns the gene BRAF and melanoma.